STXS at a glance
Stereotaxis, Inc. (STXS, SEC CIK 1289340) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Stereotaxis, Inc. (STXS) reported revenue of $32.4 million (up 20.3% from FY2024) and a net loss of $21.6 million. Diluted EPS was -$0.25.
- As of June 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Stereotaxis, Inc. (STXS) shares worth $18.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $32.4M
- +20.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $18.9M · +0 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Forward-looking risks: APT and Robocath integration, funding Robocath operations, regulatory milestones, COVID-19 impacts
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- Robocath acquisition exposure triggered by April 14, 2026 Share Sale Agreement
- European Investment Bank joined the Robocath transaction on July 7, 2026
- Resale risk from Robocath securityholders under July 7, 2026 Resale Organization Agreement
AI summary of the STXS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Section 2.02 text contains only a standard exhibit-disclaimer provision
- No operating results or financial metrics are included; investor focus should shift to the referenced exhibit, if filed
Item EX-99.1: Item EX-99.1
- Q2 revenue $7.7M, down from $8.8M, as system revenue fell to $1.5M from $3.0M
- Recurring revenue rose to $6.2M, with robotic catheter revenue exceeding $1M and growing 270% sequentially
Item 8.01: Other Events
- Acquisition closed July 7, 2026, giving Stereotaxis 100% of Robocath’s shares and voting power
- Robocath transaction expands Stereotaxis’ ownership and operating exposure to the French medical-technology business
Item EX-99.1: Item EX-99.1
- Robocath acquisition expected to increase near-term operating losses and negative cash flow, requiring potential funding of its operations
- $1.1 million in pre-closing operating loans repaid at closing, reducing stock consideration paid to Robocath equityholders
Item 3.02: Unregistered Sales of Equity Securities
- Robocath acquisition closed July 7, 2026, with Stereotaxis issuing 1,469,485 shares plus warrants for 4,575,143 shares
- Pre-funded warrants carry a par-value exercise price and expire July 7, 2031, creating substantial potential dilution
Item 8.01: Other Events
- Robocath acquisition completed July 7, 2026 for approximately $20 million in cash and common stock
- Transaction expands Stereotaxis’ strategic footprint through Robocath ownership
Item 7.01: Regulation FD Disclosure
- Standard Regulation FD disclaimer limiting Exchange Act liability for the disclosure
- No substantive business, financial, or operational information in the provided excerpt
Item EX-99.1: Item EX-99.1
- Acquisition of Robocath completed July 9, 2026, converting the previously announced transaction into an operating integration
- Expanded platform across electrophysiology, interventional cardiology, and neurointerventions, broadening Stereotaxis’s addressable market
AI summaries of STXS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STXS
Don't miss the next STXS filing
- Alerts as it files. A push when STXS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STXS, by share count.
- Ask anything. An AI agent that reads every STXS filing and answers with sources.
STXS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Benfer David | A | Jul 1, 2026 | 43,103 | - |
| Menawat Arun Swarup | A | Jul 1, 2026 | 43,103 | - |
| Levin Ross B | A | Jul 1, 2026 | 43,103 | - |
| Fischel Nathan | A | Jul 1, 2026 | 43,103 | - |
| Curet Myriam | A | Jul 1, 2026 | 43,103 | - |
| SHAMIR NACHUM | A | Jul 1, 2026 | 43,103 | - |
| Peery Kimberly R. | A | Apr 11, 2026 | 40,000 | - |
| SHAMIR NACHUM | A | Jan 2, 2026 | 46,948 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $26.9M | $32.4M |
| Gross Profit | $14.9M | $14.6M | $17.1M |
| Operating Income | - | -$24.7M | -$22.1M |
| Net Income | -$20.7M | -$24.0M | -$21.6M |
| Gross Margin | - | 54.2% | 52.7% |
| Op. Margin | - | -91.9% | -68.3% |
| Net Margin | - | -89.3% | -66.8% |
| Balance Sheet | |||
| Total Assets | $41.9M | $46.7M | $52.3M |
| Equity | - | $6.1M | $13.5M |
| ROE | - | -395.5% | -160.5% |
| Per Share | |||
| EPS | $-0.27 | $-0.30 | $-0.25 |
| Cash Flow | |||
| Operating CF | - | -$8.5M | -$13.7M |
Source: XBRL data in Stereotaxis, Inc. (STXS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate STXS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 20 | $18.9M |
| Q1 2026 | 20 | $18.8M |
| Q4 2025 | 20 | $24.5M |
| Q3 2025 | 20 | $32.6M |
| Q2 2025 | 19 | $19.9M |
| Q1 2025 | 17 | $10.5M |
| Q4 2024 | 11 | $12.7M |
| Q3 2024 | 8 | $3.7M |
- BlackRock+440.6K (+11%)
- Morgan Stanley+201.3K (+154%)
- AQR Capital Management+131.4K (+201%)
- Vanguard Portfolio Management LLC+95.0K (+26%)
- Bank of America Corp+67.6K (+136%)
- Renaissance Technologies LLC−357.2K (-96%)
- State Street Corp−41.0K (-4%)
- Goldman Sachs Group−34.1K (-13%)
- FMR LLC (Fidelity)−4.2K (-14%)
- Citadel Advisors LLC+183.1K
- Millennium Management−68.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 135 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STXS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 19, 2026 | - | - | |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | May 15, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 8-K | Apr 15, 2026 | - | Analysis | - |
| 4 | Apr 13, 2026 | - | - | - |
| 10-K | Mar 12, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 4 | Jan 2, 2026 | - | - | |
| 4 | Jan 2, 2026 | - | - | |
| 4 | Jan 2, 2026 | - | - | |
| 4 | Jan 2, 2026 | - | - | |
| 4 | Jan 2, 2026 | - | - | |
| 4 | Jan 2, 2026 | - | - | |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
STXS SEC filings: frequently asked questions
Which institutions hold STXS stock?
As of June 30, 2026, the largest Stereotaxis, Inc. (STXS) holders among the 13F filers tracked by SignalX were BlackRock ($7.6 million), Vanguard Capital Management LLC ($5.2 million), State Street Corp ($1.6 million), Northern Trust ($911,000), Vanguard Portfolio Management LLC ($797,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STXS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Stereotaxis, Inc. (STXS) reported revenue of $32.4 million (up 20.3% from FY2024) and a net loss of $21.6 million. Diluted EPS was -$0.25. The figures come from the XBRL data in the 10-K.
What did STXS report in its latest 8-K?
Stereotaxis, Inc. (STXS) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Section 2.02 text contains only a standard exhibit-disclaimer provision.
What are the latest STXS SEC filings?
Stereotaxis, Inc. (STXS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on July 1, 2026.
What is STXS's SEC CIK number?
Stereotaxis, Inc. (STXS)'s SEC Central Index Key (CIK) is 1289340. EDGAR lists every STXS filing under that number.
Ask anything about STXS
The research agent reads STXS's filings, financials, insider trades and 13F holders, then answers with sources.